Frederic Triebel, MD, PhD

home / authors / frederic-triebel-md-phd

Articles

Dr. Triebel on the Rationale for a Novel Immunotherapy Combination in Melanoma

Dr. Triebel on the Rationale for a Novel Immunotherapy Combination in Melanoma

Frederic Triebel, MD, PhD
January 30th 2019

Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immutep Ltd, discusses the rationale for a novel immunotherapy combination in patients with unresectable or metastatic melanoma.

Read More

Dr. Triebel on Novel Immunotherapy Combination in Melanoma

Dr. Triebel on Novel Immunotherapy Combination in Melanoma

Frederic Triebel, MD, PhD
November 30th 2018

Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immuntep Ltd, discusses a novel immunotherapy combination in melanoma.

Read More

Latest Updated Articles

Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Published: August 22nd 2024 | Updated: August 29th 2024
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Published: August 6th 2024 | Updated: August 19th 2024
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Caroline Robert, MD, PhD
Published: September 15th 2024 | Updated: September 19th 2024
Long-Term KEYNOTE-006 Data Support Pembrolizumab as SOC in Advanced Melanoma
Sameh Gaballa, MD
Published: August 19th 2024 | Updated: September 19th 2024
Case Studies: Three follicular lymphoma cases treated with oral tazemetostat